Diversified life-sciences and diagnostics company (bioprocessing, genomics tools, diagnostics) built through disciplined operational M&A.
Diversified life-sciences and diagnostics company (bioprocessing, genomics tools, diagnostics) built through disciplined operational M&A.
Sells instruments and tests that customers use repeatedly, so consumables and services recur once instruments are in place. It applies the Danaher Business System, a continuous-improvement method, to companies it buys, such as Cytiva in 2020, and spun off Fortive in 2016 and Veralto in 2023.
Moat: wide (switching costs, installed base, IP / patents). Installed base of bioprocessing/diagnostic instruments generates recurring, high-margin consumables revenue.
Headquarters: Washington, D.C., USA · Founded: 1969 · Employees: 60,000
Size Danaher (DHR) is a United States Health Care company (Medical Specialties) with a market value of $161B, the 74th largest of 3,085 United States companies the cockpit tracks. Shares closed at $228.58 on 18 Nov 2026.
Performance Over six months the shares gained 33.9%, against +26.2% for the median peer and -2.2% for the United States market (cap-weighted) — 5th highest of 16 in its peer set.
Growth Revenue grew 5.5% over the last twelve months (peer median +9.8%); the operating margin is 20.9% (peer median 19.9%).
Valuation It trades at 25.1× forward earnings against a peer median of 25.6× (8th cheapest of 16).
Price implies For today's price to make sense, revenue must grow about 21% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is +19 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.8 points below its cost of capital (8.4% WACC).
Backlog Backlog (remaining performance obligations) was $7.40B at 25 Sep 2026, up 51% on a year earlier — 0.3 years of trailing revenue. Backlog detail →
Credit Danaher has 8 bonds outstanding ($6.72B), rated A- by the agencies and trading like AA- at a weighted spread of 80 bp.
Short interest Short interest is 1.2% of the free float (30 Oct 2026).
Next results Next results expected around 27 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $25.6B | $24.6B | $23.9B | $23.9B | $26.6B |
| Revenue growth | — | +3% | 0% | -10% | — |
| Gross profit | $15.1B | $14.6B | $14.2B | $14.0B | $16.2B |
| EBITDA | $7.99B | $7.70B | $7.54B | $7.45B | $9.67B |
| Net income | $4.33B | $3.61B | $3.90B | $4.76B | $7.21B |
| Free cash flow | $5.73B | $5.26B | $5.30B | $5.78B | $7.40B |
| Capital expenditure | $1.13B | $1.16B | $1.39B | $1.38B | $1.12B |
| Total debt | $27.8B | $19.7B | $17.1B | $19.5B | $20.6B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Danaher DHR | $161B | +34% | +6% | 21% | 25.1× | 20.8% |
| Thermo Fisher Scientific TMO | $257B | +53% | +8% | 19% | 25.7× | 21.3% |
| Sartorius Stedim Biotech DIM.PA | $24.2B | +32% | +4% | 19% | 45.7× | 33.4% |
| Agilent Technologies A | $50.0B | +56% | +9% | 24% | 27.0× | 23.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | DHR | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +1.9% | +5.2% | 5th lowest of 16 |
| 6-month return | +33.9% | +26.2% | 5th highest of 16 |
| Distance from 52-week high | -5.5% | -9.3% | 7th highest of 16 |
| Revenue growth (TTM) | +5.5% | +9.8% | 3rd lowest of 16 |
| Operating margin | 20.9% | 19.9% | 8th highest of 16 |
| Forward P/E | 25.1× | 25.6× | 8th cheapest of 16 |
| Growth the price implies (Req g, 7 yrs) | 20.8% | 16.5% | 6th most demanding of 16 |
| Growth delivered (Del g) | +2.0% | +6.7% | 2nd lowest of 16 |
| Hurdle (Req g minus delivered) | +18.8 pp | +6.0 pp | 3rd most demanding of 16 |
| ROIC minus cost of capital | -2.8 pp | +1.9 pp | 3rd lowest of 16 |
| EV / EBITDA | 22.9× | 19.3× | 7th most expensive of 16 |
| Net debt / EBITDA | 2.8× | 1.9× | 4th most indebted of 16 |
| Bond spread | 80 bp | 73 bp | 2nd widest of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Danaher DHR | United States | $161B | +34% | +6% | 21% | 25.1× | 20.8% | +2.0% |
| Intuitive Surgical ISRG | United States | $146B | -6% | +20% | 32% | 34.8× | 29.6% | +18.2% |
| Abbott Laboratories ABT | United States | $181B | +18% | +10% | 14% | 17.9× | 16.5% | +5.1% |
| Medtronic MDT | United States | $129B | +30% | +10% | 20% | 16.8× | 9.1% | +3.8% |
| Stryker SYK | United States | $121B | -1% | +8% | 25% | 19.9× | 10.7% | +11.8% |
| Thermo Fisher Scientific TMO | United States | $257B | +53% | +8% | 19% | 25.7× | 21.3% | +6.7% |
| EssilorLuxottica EL.PA | France | $91.9B | +5% | +8% | 12% | 24.8× | 18.4% | +14.6% |
| Boston Scientific BSX | United States | $63.3B | -23% | +9% | 21% | 14.1× | 5.8% | +15.2% |
| Edwards Lifesciences EW | United States | $60.5B | +27% | +13% | 29% | 32.3× | 17.1% | +6.7% |
| Becton Dickinson BDX | United States | $58.9B | +48% | -7% | 16% | 16.3× | -1.6% | +0.3% |
| Idexx Laboratories IDXX | United States | $55.0B | +26% | +12% | 32% | 42.9× | 29.0% | +9.7% |
| Siemens Healthineers SHL.DE | Germany | $53.7B | +27% | +1% | 14% | 18.9× | 9.6% | +5.6% |
| Medline MDLN | United States | $51.5B | +8% | +12% | 6% | 25.6× | 15.9% | +9.9% |
| Agilent Technologies A | United States | $50.0B | +56% | +9% | 24% | 27.0× | 23.3% | +5.4% |
| Hoya 7741.T | Japan | $49.0B | -16% | +13% | 32% | 27.7× | 14.1% | +11.6% |
| Waters WAT | United States | $45.8B | +37% | +81% | 10% | 29.1× | 48.1% | +6.0% |
Danaher has 8 bonds outstanding with $6.72B face value. The agencies rate it A-; its bonds trade like AA-. Weighted yield 4.84%, a spread of 80 bp over government bonds.
Danaher reported $7.40B of remaining performance obligations at 25 Sep 2026, up 51% from a year earlier and down 1% from the previous quarter. That is 0.3 years of trailing revenue already under contract. Book-to-bill last quarter: 0.98.